We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
AtriCure (ATRC - Free Report) shares rallied 6.2% in the last trading session to close at $28.8. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.5% loss over the past four weeks.
The sharp rise in ATRC shares can be attributed to renewed investor optimism surrounding the company's long-term growth prospects following its presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its goal of reaching $1 billion in revenue by 2030 and highlighted the significant market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also appear to be re-pricing the value of these pivotal studies, particularly after AtriCure disclosed accelerated enrollment in the BoxX-NoAF trial and emphasized that positive outcomes could substantially broaden its addressable market.
This medical device maker is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of +250%. Revenues are expected to be $151.5 million, up 11.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For AtriCure, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRC going forward to see if this recent jump can turn into more strength down the road.
AtriCure is a member of the Zacks Medical - Products industry. One other stock in the same industry, QuidelOrtho (QDEL - Free Report) , finished the last trading session 4.1% higher at $13.67. QDEL has returned 10.2% over the past month.
For QuidelOrtho, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.04. This represents a change of -66.7% from what the company reported a year ago. QuidelOrtho currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC - Free Report) shares rallied 6.2% in the last trading session to close at $28.8. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.5% loss over the past four weeks.
The sharp rise in ATRC shares can be attributed to renewed investor optimism surrounding the company's long-term growth prospects following its presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its goal of reaching $1 billion in revenue by 2030 and highlighted the significant market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also appear to be re-pricing the value of these pivotal studies, particularly after AtriCure disclosed accelerated enrollment in the BoxX-NoAF trial and emphasized that positive outcomes could substantially broaden its addressable market.
This medical device maker is expected to post quarterly earnings of $0.03 per share in its upcoming report, which represents a year-over-year change of +250%. Revenues are expected to be $151.5 million, up 11.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For AtriCure, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
AtriCure is a member of the Zacks Medical - Products industry. One other stock in the same industry, QuidelOrtho (QDEL - Free Report) , finished the last trading session 4.1% higher at $13.67. QDEL has returned 10.2% over the past month.
For QuidelOrtho, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.04. This represents a change of -66.7% from what the company reported a year ago. QuidelOrtho currently has a Zacks Rank of #3 (Hold).